TAKNYSEPharmaceutical PreparationsAlso trades as TKPHF
TAKEDA PHARMACEUTICAL CO LTD
Financials through fiscal 2026, year ended Mar 31, 2026Last filing: 20-F on Jun 17, 2026
$19.61−0.06 (-0.31%)
Close on Oct 19, 2026
TAKEDA PHARMACEUTICAL CO LTD revenue by segment
By business segment
By product or service
| Revenue | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales of pharmaceutical products | ¥4.42T | ¥4.50T | ¥4.16T | ¥3.92T | ¥3.30T | ¥3.11T | ¥3.20T | ¥2.03T | ¥1.69T | ¥1.67T | 98.2% | -1.6% |
| Total Gastroenterology | ¥1.41T | ¥1.36T | ¥1.22T | ¥1.09T | ¥875.69B | ¥777.80B | ¥697.90B | ¥539.32B | ¥452.03B | – | 31.2% | +3.7% |
| Total PDT | ¥1.06T | ¥1.03T | ¥903.70B | ¥765.36B | – | – | – | – | – | – | 23.5% | +2.4% |
| ENTYVIO | ¥958.04B | ¥914.10B | ¥800.92B | ¥702.74B | ¥521.78B | ¥429.28B | ¥347.20B | ¥269.20B | ¥201.35B | – | 21.3% | +4.8% |
| Immunoglobulin | ¥790.57B | ¥757.77B | ¥644.59B | ¥522.21B | ¥385.86B | ¥334.87B | ¥298.70B | ¥73.46B | ¥12.25B | – | 17.5% | +4.3% |
| Total Rare Diseases | ¥762.70B | ¥752.82B | ¥688.42B | ¥639.77B | ¥611.20B | ¥591.75B | ¥634.89B | ¥129.42B | ¥0 | – | 16.9% | +1.3% |
| Total Oncology | ¥580.13B | ¥560.43B | ¥462.36B | ¥438.74B | ¥468.73B | ¥416.51B | ¥420.96B | ¥399.44B | ¥377.42B | – | 12.9% | +3.5% |
| Total Neuroscience | ¥414.34B | ¥565.82B | ¥627.01B | ¥637.71B | ¥482.29B | ¥417.30B | ¥438.52B | ¥154.67B | ¥82.11B | – | 9.2% | -26.8% |
| Total Other | ¥223.96B | ¥257.39B | ¥315.70B | ¥372.69B | ¥624.15B | ¥574.07B | ¥704.76B | ¥780.90B | ¥842.55B | – | 5.0% | -13.0% |
| TAKHZYRO | ¥223.92B | ¥223.16B | ¥178.68B | ¥151.80B | ¥103.24B | ¥86.72B | ¥68.27B | ¥9.73B | ¥0 | – | 5.0% | +0.3% |
| Others | ¥207.98B | ¥237.67B | ¥268.54B | ¥286.26B | ¥534.24B | ¥460.10B | ¥596.26B | ¥624.49B | ¥699.86B | – | 4.6% | -12.5% |
| VYVANSE/ELVANSE | ¥203.23B | ¥350.61B | ¥423.22B | ¥459.29B | ¥327.05B | ¥271.53B | ¥274.08B | – | – | – | 4.5% | -42.0% |
| GATTEX/REVESTIVE | ¥145.66B | ¥146.29B | ¥119.25B | ¥93.08B | ¥75.75B | ¥64.56B | ¥61.81B | ¥12.75B | ¥0 | – | 3.2% | -0.4% |
| TAKECAB/VOCINTI | ¥143.68B | ¥130.76B | ¥118.53B | ¥108.72B | – | – | – | – | – | – | 3.2% | +9.9% |
| Albumin | ¥140.32B | ¥141.38B | ¥133.99B | ¥121.45B | ¥90.04B | ¥57.58B | ¥67.22B | ¥12.30B | ¥2.39B | – | 3.1% | -0.8% |
| ADCETRIS | ¥140.21B | ¥129.03B | ¥109.43B | ¥83.94B | ¥69.19B | ¥59.43B | ¥52.67B | ¥42.90B | ¥38.51B | – | 3.1% | +8.7% |
| TRINTELLIX | ¥121.84B | ¥125.74B | ¥104.80B | ¥100.08B | ¥82.32B | ¥68.87B | ¥70.67B | ¥57.55B | ¥48.37B | – | 2.7% | -3.1% |
| LEUPLIN/ENANTONE | ¥120.79B | ¥119.27B | ¥107.35B | ¥111.31B | ¥106.46B | ¥95.37B | ¥109.05B | – | – | – | 2.7% | +1.3% |
| Others | ¥111.51B | ¥117.17B | ¥119.72B | ¥92.30B | – | ¥0 | ¥0 | – | – | – | 2.5% | -4.8% |
| Others | ¥106.78B | ¥102.39B | ¥111.15B | ¥75.11B | ¥82.88B | ¥99.66B | ¥103.54B | ¥68.25B | ¥70.62B | – | 2.4% | +4.3% |
| ADVATE | ¥105.52B | ¥111.76B | ¥122.91B | ¥118.19B | ¥118.49B | ¥128.54B | ¥157.86B | ¥32.10B | ¥0 | – | 2.3% | -5.6% |
| ELAPRASE | ¥100.49B | ¥97.24B | ¥91.56B | ¥85.32B | ¥73.12B | ¥68.79B | ¥67.92B | ¥15.08B | ¥0 | – | 2.2% | +3.3% |
| Out-licensing and service income | ¥82.61B | ¥85.58B | ¥100.11B | ¥105.20B | ¥273.28B | ¥92.44B | ¥87.04B | ¥70.95B | ¥76.69B | ¥60.14B | 1.8% | -3.5% |
| NINLARO | ¥82.11B | ¥91.24B | ¥87.36B | ¥92.69B | ¥91.20B | ¥87.40B | ¥77.56B | ¥62.17B | ¥46.43B | – | 1.8% | -10.0% |
| REPLAGAL | ¥80.43B | ¥77.85B | ¥73.55B | ¥66.74B | ¥51.71B | ¥51.76B | ¥51.25B | ¥11.44B | ¥0 | – | 1.8% | +3.3% |
| ICLUSIG | ¥75.05B | ¥70.73B | ¥54.71B | ¥47.21B | ¥34.86B | ¥34.19B | ¥31.82B | ¥28.71B | ¥23.12B | – | 1.7% | +6.1% |
| Others | ¥69.92B | ¥65.78B | ¥64.92B | ¥83.04B | ¥42.37B | ¥30.21B | ¥24.31B | ¥22.52B | ¥21.15B | – | 1.6% | +6.3% |
| Others | ¥68.39B | ¥68.49B | ¥65.06B | ¥121.70B | – | – | – | – | – | – | 1.5% | -0.1% |
| Others | ¥64.52B | ¥61.04B | ¥57.24B | ¥49.75B | ¥33.10B | ¥76.90B | ¥93.78B | ¥47.77B | ¥33.73B | – | 1.4% | +5.7% |
| Total Vaccines | ¥59.61B | ¥55.41B | ¥50.36B | ¥78.66B | – | – | – | – | – | – | 1.3% | +7.6% |
| ADYNOVATE/ADYNOVI | ¥56.69B | ¥64.61B | ¥66.31B | ¥66.55B | ¥60.73B | ¥58.07B | ¥58.67B | – | – | – | 1.3% | -12.3% |
| FRUZAQLA | ¥55.11B | ¥47.95B | ¥10.08B | ¥0 | ¥0 | – | – | – | – | – | 1.2% | +14.9% |
| LIVTENCITY | ¥46.91B | ¥33.00B | ¥19.09B | ¥10.50B | – | – | – | – | – | – | 1.0% | +42.2% |
| QDENGA | ¥40.77B | ¥35.58B | ¥9.56B | ¥144.00M | – | – | – | – | – | – | 0.9% | +14.6% |
| DEXILANT | ¥37.26B | ¥38.55B | ¥45.28B | ¥69.37B | ¥50.76B | ¥55.57B | ¥62.80B | ¥69.20B | ¥65.74B | – | 0.8% | -3.3% |
| ALUNBRIG | ¥36.93B | ¥36.43B | ¥28.52B | ¥20.56B | ¥13.64B | ¥8.81B | ¥7.24B | ¥5.20B | ¥2.83B | – | 0.8% | +1.4% |
| FEIBA | ¥32.87B | ¥39.43B | ¥40.54B | ¥41.27B | ¥39.16B | ¥44.50B | ¥51.51B | – | – | – | 0.7% | -16.6% |
| HEMOFIL/IMMUNATE/IMMUNINE | ¥25.38B | ¥25.59B | ¥19.52B | ¥19.58B | ¥17.72B | ¥18.66B | – | – | – | – | 0.6% | -0.8% |
| VONVENDI | ¥25.28B | ¥20.93B | ¥16.19B | ¥12.22B | ¥8.77B | – | – | – | – | – | 0.6% | +20.8% |
| ADDERALL XR | ¥24.75B | ¥28.43B | ¥41.76B | ¥28.59B | ¥20.89B | – | ¥24.31B | ¥5.40B | ¥0 | – | 0.5% | -13.0% |
| Others | ¥18.84B | ¥19.83B | ¥40.80B | ¥78.52B | – | – | – | – | – | – | 0.4% | -5.0% |
| ADZYNMA | ¥11.96B | ¥7.08B | ¥425.00M | ¥0 | – | – | – | – | – | – | 0.3% | +68.8% |
| FOSRENOL | ¥8.84B | ¥7.91B | ¥13.53B | ¥13.53B | ¥13.61B | – | – | – | – | – | 0.2% | +11.8% |
| EOHILIA | ¥8.78B | ¥5.45B | ¥200.00M | ¥0 | – | – | – | – | – | – | 0.2% | +61.0% |
| RESOLOR/MOTEGRITY | ¥7.26B | ¥19.48B | ¥20.88B | – | – | – | – | – | – | – | 0.2% | -62.7% |
| AZILVA | ¥7.14B | ¥11.81B | ¥33.64B | ¥72.90B | – | – | – | – | – | – | 0.2% | -39.5% |
| ADYNOVATE/ADYNOVI | – | – | – | – | – | ¥58.07B | ¥58.67B | ¥10.74B | ¥0 | – | – | – |
| ALOFISEL | – | – | ¥3.51B | ¥2.73B | ¥1.84B | ¥784.00M | ¥373.00M | ¥45.00M | ¥0 | – | – | – |
| AZILVA-F | – | – | ¥33.64B | ¥72.90B | ¥76.30B | ¥82.21B | ¥76.75B | ¥70.76B | ¥63.97B | – | – | – |
| Cinryze | – | – | – | – | – | – | ¥24.35B | ¥3.10B | ¥0 | – | – | – |
| FEIBA | – | – | – | – | – | ¥44.50B | ¥51.51B | ¥9.63B | ¥0 | – | – | – |
| FIRAZYR | – | – | – | – | ¥26.69B | ¥26.82B | ¥32.66B | ¥6.42B | ¥0 | – | – | – |
| Total Hereditary Angioedema | – | – | – | – | ¥153.59B | ¥139.33B | ¥129.82B | ¥20.42B | ¥0 | – | – | – |
| Kalbitor | – | – | – | – | – | – | ¥4.54B | ¥1.17B | ¥0 | – | – | – |
| LEUPLIN/ENANTONE | – | – | – | – | – | ¥95.37B | ¥109.05B | ¥110.07B | ¥108.06B | – | – | – |
| LOTRIGA | – | – | – | ¥16.73B | ¥32.69B | ¥31.77B | ¥31.75B | ¥30.86B | ¥28.49B | – | – | – |
| NATPARA/NATPAR | – | – | – | – | – | ¥3.55B | ¥13.64B | ¥7.09B | ¥0 | – | – | – |
| NESINA/VIPIDIA-F | – | – | – | – | – | ¥57.67B | ¥57.96B | ¥54.79B | ¥50.23B | – | – | – |
| Others | – | – | ¥39.99B | ¥34.79B | ¥31.05B | ¥27.94B | ¥28.25B | ¥7.72B | ¥1.79B | – | – | – |
| Others | – | – | ¥47.30B | ¥53.73B | ¥44.24B | ¥26.65B | ¥49.12B | ¥11.46B | ¥0 | – | – | – |
| PANTOLOC/CONTROLOC | – | – | – | – | – | ¥43.12B | ¥49.46B | ¥61.63B | ¥65.83B | – | – | – |
| Total PDT Immunology | – | – | ¥818.57B | ¥678.44B | ¥506.95B | ¥420.39B | ¥394.17B | ¥93.48B | ¥16.43B | – | – | – |
| Total Rare Hematology | – | – | ¥305.30B | ¥304.72B | ¥283.69B | ¥289.80B | ¥334.24B | ¥66.70B | ¥0 | – | – | – |
| Total Rare Metabolic | – | – | – | – | ¥172.60B | ¥162.62B | ¥170.83B | ¥42.30B | ¥0 | – | – | – |
| TAKECAB-F | – | – | – | – | ¥102.40B | ¥84.82B | ¥72.71B | ¥58.24B | ¥48.49B | – | – | – |
| VELCADE | – | – | ¥5.54B | ¥27.76B | ¥110.05B | ¥101.11B | ¥118.32B | ¥127.87B | ¥137.31B | – | – | – |
| VPRIV | – | ¥53.46B | ¥51.30B | ¥48.37B | ¥42.41B | ¥38.52B | ¥38.01B | ¥8.69B | ¥0 | – | – | – |
| VYVANSE/ELVANSE | – | – | – | – | – | ¥271.53B | ¥274.08B | ¥49.35B | ¥0 | – | – | – |
| Others | – | – | – | – | ¥23.65B | ¥25.79B | ¥28.89B | ¥4.27B | – | – | – | – |
| RECOMBINATE | – | – | – | – | – | ¥13.39B | ¥17.09B | ¥2.77B | – | – | – | – |
| NATPARA/NATPAR | – | – | – | – | ¥5.35B | ¥3.55B | ¥13.64B | – | – | – | – | – |
| PANTOLOC/CONTROLOC | – | ¥44.59B | ¥46.50B | ¥45.52B | ¥40.28B | ¥43.12B | ¥49.46B | – | – | – | – | – |
| RECOMBINATE | – | – | ¥12.05B | ¥12.76B | ¥12.30B | ¥13.39B | ¥17.09B | – | – | – | – | – |
| LIVTENCITY | – | – | ¥19.09B | ¥10.50B | ¥1.33B | ¥0 | – | – | – | – | – | – |
| TAKECAB/VOCINTI | – | – | ¥118.53B | ¥108.72B | ¥102.40B | ¥84.82B | – | – | – | – | – | – |
| EXKIVITY | – | – | ¥3.46B | ¥3.73B | ¥962.00M | ¥0 | – | – | – | – | – | – |
| Total Rare Genetics and Other | – | – | ¥465.40B | ¥418.72B | ¥327.51B | ¥301.95B | – | – | – | – | – | – |
| Others | – | – | ¥51.23B | ¥55.99B | ¥55.70B | ¥56.16B | – | – | – | – | – | – |
| Diabetes | – | – | – | – | ¥133.04B | – | – | – | – | – | – | – |
| Intuniv | – | – | ¥33.56B | ¥16.35B | ¥18.94B | – | – | – | – | – | – | – |
By region
| Revenue | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | ¥2.16T | ¥2.38T | ¥2.20T | ¥2.10T | ¥1.71T | ¥1.57T | ¥1.60T | ¥828.99B | ¥598.34B | ¥520.16B | 48.0% | -9.0% |
| Europe and Canada | ¥1.15T | ¥1.06T | ¥966.84B | ¥842.67B | ¥739.17B | ¥666.18B | ¥645.53B | ¥405.64B | ¥313.72B | ¥279.69B | 25.4% | +8.6% |
| Japan | ¥433.11B | ¥418.46B | ¥451.39B | ¥512.04B | ¥658.98B | ¥559.75B | ¥592.79B | ¥571.02B | ¥580.35B | ¥655.34B | 9.6% | +3.5% |
| Latin America | ¥254.13B | ¥235.85B | ¥198.10B | ¥160.38B | ¥128.47B | ¥121.64B | ¥143.46B | ¥88.12B | ¥75.66B | ¥72.52B | 5.6% | +7.8% |
| China | ¥195.14B | ¥191.74B | ¥174.84B | ¥150.97B | – | – | – | – | – | – | 4.3% | +1.8% |
| Other | ¥133.89B | ¥128.85B | ¥117.91B | ¥95.18B | ¥68.95B | ¥68.52B | ¥71.26B | ¥38.32B | ¥30.19B | ¥33.99B | 3.0% | +3.9% |
| Asia (excluding Japan & China) | ¥98.67B | ¥99.39B | ¥86.38B | ¥74.03B | – | – | – | – | – | – | 2.2% | -0.7% |
| Russia/CIS | ¥79.72B | ¥72.36B | ¥72.59B | ¥88.43B | ¥62.06B | ¥57.56B | ¥76.84B | ¥59.74B | ¥68.24B | ¥57.55B | 1.8% | +10.2% |
| Asia | – | – | – | – | – | ¥156.24B | ¥165.40B | ¥105.41B | ¥104.03B | ¥112.80B | – | – |
| Asia (excluding Japan) | – | – | ¥261.22B | ¥225.01B | ¥196.96B | ¥156.24B | ¥165.40B | – | – | – | – | – |
From the segment and revenue-disaggregation notes of Takeda Pharmaceutical's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.